FX 005

Drug Profile

FX 005

Alternative Names: FX-005

Latest Information Update: 25 Sep 2015

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer Flexion Therapeutics
  • Class Analgesics
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Musculoskeletal pain

Most Recent Events

  • 25 Sep 2015 FX 005 is still in phase-I/II development for Musculoskeletal pain in Austria, Canada, Spain and the United Kingdom
  • 30 May 2012 Flexion Therapeutics plans a phase IIb trial for Musculoskeletal pain
  • 30 May 2012 Interim efficacy and adverse events data from a phase I/II trial in Musculoskeletal pain released by Flexion Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top